Senti Biosciences Inc (SNTI) Stock Price, Quote & News

Company Profile

Senti Biosciences, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. Its lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need. The company's product candidates also include SENTI-202, a logic gated off-the-shelf...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 239 2030

Website: www.sentibio.com

Address:

2 Corporate Drive, First Floor, South San Francisco, United States

Mrpierce87 Aug. 15 at 5:13 AM

Thoughts on $SNTI

1 · Reply

Gutfreund22 Aug. 12 at 6:06 PM

$SHPH $SNTI $VRAX $EQ exploded to $0.95 and has been consolidating in a tight range. The largest volume cluster is at $0.90, making that my key support. Above $0.935, there’s room to retest $0.95 and possibly push to $1.00. If $0.90 fails, I’d expect a retrace toward $0.80.

0 · Reply

Livermore124 Aug. 12 at 5:51 PM

$GFAI $SNTI $BNED $BJDX spiked to $1.73 but retraced to $1.57 support. The biggest volume stack is between $1.57 and $1.58. If it holds this zone, I’m looking for a bounce back toward $1.68 and $1.73. If it loses $1.57, it may revisit $1.50 or lower.

0 · Reply

DetectingRunners Aug. 12 at 5:43 PM

$SNTI Due for a pop

0 · Reply

DM0n3y Aug. 11 at 6:12 PM

$IPA $FATE $SNTI $ALEC Adding these today. #AItrading

0 · Reply

None_ Aug. 11 at 6:42 AM

$SNTI https://www.biospace.com/press-releases/senti-bio-reports-second-quarter-2025-financial-results-and-confirms-next-data-milestone-for-phase-1-senti-202-study-in-acute-myeloid-leukemia-aml-expected-q4-2025

0 · Reply

JoseGilberto109 Aug. 8 at 11:16 PM

Wow what is happening to SNSE right now!? Seems like ALL volume and momentum are shifting into SNSE!! Could it be the next crazy runner of the day?? Only 500k float on SNSE - Bulls should keep it on watch!! Also watching: $ALLR $SINT $SNTG $SNTI bio

0 · Reply

ZhaoSonsWealth Aug. 7 at 7:18 PM

IBG Low-float with no dilution are rare and this one’s sitting at the floor. The chart is coiled. The tape is quiet. One merger PR and it gaps before most can react. I’m not waiting for the alert. I’m already in. $PRST $SNTI $BFRG $PHGE

2 · Reply

None_ Aug. 6 at 7:54 PM

$SNTI https://www.biospace.com/press-releases/senti-bio-determines-recommended-phase-2-dose-rp2d-in-phase-1-study-of-senti-202-for-the-treatment-of-relapsed-refractory-hematologic-malignancies-including-acute-myeloid-leukemia

0 · Reply

ZhaoSonsWealth Aug. 4 at 3:40 PM

Keep eyes on IBG, positive stuff coming + $43 price target IBG You won’t get a warning. Low float. No dilution. No hype… yet. One merger catalyst and this won’t just run it’ll gap hard and leave you behind. This is how the biggest runners start. $SNTI $SNMP $MBRX $VCNX

3 · Reply

Senti Biosciences to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Aug 12, 2025, 9:15 AM EDT - 5 days ago

Senti Bio Participates in Virtual Investor “What This Means” Segment Discussing The Phase 2 Dose and Schedule Selection for SENTI-202 in its Clinical Trial for Acute Myeloid Leukemia

Aug 7, 2025, 8:05 AM EDT - 10 days ago

Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025

$Senti Bio Determines Recommended Phase 2 Dose (RP2D) in Phase 1 Study of SENTI-202 for the Treatment of Relapsed/Refractory Hematologic Malignancies, Including Acute Myeloid Leukemia$

Aug 5, 2025, 8:30 AM EDT - 12 days ago

Senti Bio Determines Recommended Phase 2 Dose (RP2D) in Phase 1 Study of SENTI-202 for the Treatment of Relapsed/Refractory Hematologic Malignancies, Including Acute Myeloid Leukemia

Jul 22, 2025, 8:45 AM EDT - 26 days ago

Senti Biosciences Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Jul 21, 2025, 8:55 AM EDT - 27 days ago

Senti Bio's Chief Medical Officer, Kanya Rajangam, M.D., Ph.D. to Give Feature Presentation at the BioScience Forum

Jul 18, 2025, 8:55 AM EDT - 4 weeks ago

Senti Bio Appoints Entrepreneurial Leader and Investor, Bryan Baum, to Board of Directors

Jun 30, 2025, 9:15 AM EDT - 6 weeks ago

Senti Bio Participates in Nasdaq Amplify Spotlight Series

Jun 24, 2025, 8:45 AM EDT - 7 weeks ago

Senti Bio to Present at the 2025 Synthetic Biology: Engineering, Evolution, & Design (SEED) Conference

Jun 18, 2025, 7:00 AM EDT - 2 months ago

Senti Bio Granted U.S. FDA Orphan Drug Designation for Use of First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 to Treat Acute Myeloid Leukemia

Jun 9, 2025, 4:30 PM EDT - 2 months ago

Senti Biosciences Announces New Employment Inducement Grants

Jun 6, 2025, 9:05 AM EDT - 2 months ago

Senti Bio to Participate in a Virtual Fireside Chat Hosted by Chardan Capital Markets, LLC

May 30, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Senti Biosciences, Inc. (SNTI) Shareholders to Inquire about Securities Investigation

May 29, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Senti Biosciences, Inc. (SNTI) And Encourages Shareholders to Connect

May 28, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Senti Biosciences, Inc. (SNTI) And Encourages Shareholders to Reach Out

May 27, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Senti Biosciences, Inc. (SNTI) and Encourages Shareholders to Learn More About the Investigation

May 26, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Senti Biosciences, Inc. (SNTI) and Encourages Investors to Learn More About the Investigation

May 25, 2025, 10:00 AM EDT - 3 months ago

Senti Biosciences, Inc. (SNTI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

May 23, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Senti Biosciences, Inc. (SNTI) And Encourages Investors to Connect

May 22, 2025, 4:05 PM EDT - 3 months ago

Senti Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

May 22, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Senti Biosciences, Inc. (SNTI) Stockholders to Inquire about Securities Investigation

May 22, 2025, 8:30 AM EDT - 3 months ago

Senti Bio Receives Additional $1.0 Million Tranche from California Institute for Regenerative Medicines (CIRM) Grant for Advancing Clinical Development of SENTI-202

May 21, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Senti Biosciences, Inc. (SNTI) Investors to Inquire about Securities Investigation

May 20, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Senti Biosciences, Inc. (SNTI) And Encourages Investors to Reach Out

May 20, 2025, 5:28 AM EDT - 3 months ago

SNTI Investors Have Opportunity to Join Senti Biosciences, Inc. Fraud Investigation with the Schall Law Firm

May 19, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Senti Biosciences, Inc. (SNTI) And Encourages Stockholders to Reach Out

May 18, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Senti Biosciences, Inc. (SNTI) And Encourages Stockholders to Connect

May 16, 2025, 2:00 PM EDT - 3 months ago

Senti Biosciences, Inc. (SNTI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

May 8, 2025, 8:35 AM EDT - 3 months ago

Senti Bio Releases Mechanism of Action Video for First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202

May 6, 2025, 4:35 PM EDT - 3 months ago

Senti Bio Reports First Quarter 2025 Financial Results and Provides a Corporate Update on Positive SENTI-202 Clinical Development

May 1, 2025, 9:15 AM EDT - 3 months ago

Senti Bio Releases Virtual Investor “What This Means” Segment

Apr 30, 2025, 9:00 AM EDT - 3 months ago

Senti Bio to Present at the Citizens JMP Life Sciences Conference

$Senti Bio's SENTI-202, a First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, Demonstrates Positive Preliminary Clinical Results in the Treatment of Patients with Relapsed/Refractory AML$

Apr 28, 2025, 7:00 AM EDT - 3 months ago

Senti Bio's SENTI-202, a First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, Demonstrates Positive Preliminary Clinical Results in the Treatment of Patients with Relapsed/Refractory AML

Apr 24, 2025, 8:35 AM EDT - 4 months ago

Senti Bio to Host Conference Call and Webcast to Discuss SENTI-202 Clinical Data Being Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 on Monday, April 28th at 8:30 AM ET

Apr 21, 2025, 9:05 AM EDT - 4 months ago

Senti Bio Participates in a Virtual Investor KOL Connect Segment

Apr 16, 2025, 9:15 AM EDT - 4 months ago

Senti Bio (NASDAQ: SNTI) to Participate in a Live Virtual Investor Closing Bell Segment

Apr 10, 2025, 8:45 AM EDT - 4 months ago

Senti Bio Bolsters Scientific Advisory Board with Appointment of James B. Trager, Ph.D.

Apr 7, 2025, 8:45 AM EDT - 4 months ago

Senti Bio Joins Webull Corporate Connect Service Platform

Apr 3, 2025, 9:00 AM EDT - 4 months ago

Senti Bio to Showcase SENTI-202 Clinical Data and Novel Logic Gated Gene Circuit Mechanism of Action in Oral and Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025

Mrpierce87 Aug. 15 at 5:13 AM

Thoughts on $SNTI

1 · Reply

Gutfreund22 Aug. 12 at 6:06 PM

0 · Reply

Livermore124 Aug. 12 at 5:51 PM

0 · Reply

DetectingRunners Aug. 12 at 5:43 PM

$SNTI Due for a pop

0 · Reply

DM0n3y Aug. 11 at 6:12 PM

$IPA $FATE $SNTI $ALEC Adding these today. #AItrading

0 · Reply

None_ Aug. 11 at 6:42 AM

0 · Reply

JoseGilberto109 Aug. 8 at 11:16 PM

0 · Reply

ZhaoSonsWealth Aug. 7 at 7:18 PM

2 · Reply

None_ Aug. 6 at 7:54 PM

0 · Reply

ZhaoSonsWealth Aug. 4 at 3:40 PM

3 · Reply

AllandaleCapital Jul. 31 at 2:43 PM

$SNTI 🚨 Snapshot – Gene Circuits & Capital Circuits 💰 Mkt Cap: $46.2M | Float: 12.87M 🏦 Cash: ~$18.3M | Burn: ~$14M/Q | ~4 months runway 📉 Dilution Stack 🔹 31.7M warrants @ $2.30 (Dec 2024, 5-year tail) — Held by: Celadon, NEA, Bayer, Nantahala, Armistice, CVI, Red Hook, Empery, PharmaEssentia 🔹 21.15M shares from Series A Convertible Preferred — Fully converted @ $2.25 | Same holders 🔹 Total: >52M shares of dilutive paper waiting post-Dec unlock 🔐 All with customary anti-dilution protections 📊 Outstanding shares today: 26M 📈 Fully diluted overhang: >78M shares 🧾 ATM & Equity Line Firepower – $17.5M Leerink ATM (Mar 2025) – 100% untouched – $49M Chardan Equity Line - 98% capacity remaining – $300M Shelf (Mar 2025) ↳ Baby shelf restricted ↳ Must trade > $5.83 to lift cap ↳ IB6 float value: $49.4M

0 · Reply

Phantom_OfThe_Retrrrd Jul. 26 at 11:04 PM

L2 action reminds me of how $SNTI used to act before it ripped. $OLB is stealthy right now.

0 · Reply

KhalidsCapital Jul. 25 at 3:54 PM

Watch FGL Hidden near a dollar. 2.7 million users. AI platform + blockchain rollout this quarter. If this breaks $2 with volume, it's not coming back. One of the cleanest asymmetric plays in the market right now. Multiple catalysts $SNTI $POET $PRST $LHDX

0 · Reply

MajorGainz7 Jul. 24 at 12:12 PM

$SNTI $3+ coming

0 · Reply

Moneymike314 Jul. 18 at 8:40 PM

$SNTI Pop like last week please

0 · Reply

BioTuesdays Jul. 18 at 8:38 PM

Senti Bio has announced the appointment of entrepreneurial leader and investor Bryan Baum to its board of directors (BOD) $SNTI https://biotuesdays.com/2025/07/18/bryan-baum-joins-sentis-bod/

0 · Reply

juliio101 Jul. 18 at 4:23 PM

$SNTI $SINT $BBAI $WOLF you've been at this balance for 2 years now. If you're going to lie atleast change the number's around a bit.

1 · Reply

Moneypa Jul. 18 at 1:06 PM

$SNTI SOUTH SAN FRANCISCO, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it has appointed Bryan Baum to its Board of Directors. Mr. Baum is a serial entrepreneur and investor and is the Co-Founder and Managing Partner of K5 Global. His portfolio includes category-defining companies such as SpaceX, xAI, Anduril, Canva, Databricks, Grafana, OpenAI, and others. He has also founded and successfully exited multiple ventures.

0 · Reply

RunningandGunning Jul. 18 at 4:33 AM

$WINT 🚨🔥 ALERT — SHARES RUNNING OUT! 🔥🚨 Tiny float, massive volume, ready to explode 🚀💥 Watching it curl like $SNTI & $COSM 🦍📈 Don’t sleep — this one’s about to blow! 💣💰💸💵

1 · Reply

RunningandGunning Jul. 18 at 4:32 AM

$CLNV 🚨🔥 $WINT ALERT — SHARES RUNNING OUT! 🔥🚨 Tiny float, massive volume, ready to explode 🚀💥 Watching it curl like $SNTI & $COSM 🦍📈 Don’t sleep — this one’s about to blow! 💣💰💸💵

1 · Reply

ThebookofEli Jul. 17 at 11:28 PM

$SNTI I like it here

0 · Reply

MajorGainz7 Jul. 17 at 9:32 PM

$SNTI

0 · Reply

Market Cap	39.76M
Revenue (ttm)	0.00
Net Income (ttm)	-52.79M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	74,600
Avg Vol	384,176
Day's Range	N/A - N/A
Shares Out	26.16M
Stochastic %K	22%
Beta	2.07
Analysts	Strong Sell
Price Target	$12.00